1,122 results on '"Delforge, Michel"'
Search Results
2. Teclistamab in Relapsed or Refractory Multiple Myeloma
3. Side Effects of Treatment in Multiple Myeloma
4. Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)
5. Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma
6. Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma
7. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial
8. Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study
9. Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma
10. Safety results from the phase 3 MajesTEC-7 study in patients (pts) with transplant ineligible/not intended newly diagnosed multiple myeloma (NDMM).
11. Advancing Amyloidosis Management in Belgium: The Belgian Amyloidosis Consortium (Be.Amycon)
12. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network
13. Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial
14. Predictors of Lenalidomide Refractory Relapse Timing With Newly Diagnosed Multiple Myeloma: A FIRST Trial Subanalysis
15. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma
16. Plain Language Summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma
17. Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma
18. The Phase 2 Cartitude-2 Trial: Updated Efficacy and Safety of Ciltacabtagene Autoleucel in Patients with Multiple Myeloma and 1–3 Prior Lines of Therapy (Cohort A) and with Early Relapse after First Line Treatment (Cohort B)
19. Patient experience before and after treatment with idecabtagene vicleucel (ide-cel, bb2121): qualitative analysis of patient interviews in the KarMMa trial
20. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial
21. Proliferative glomerulonephritis with monoclonal immunoglobulin deposits in the native or posttransplant kidney.
22. COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
23. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial
24. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
25. Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial
26. Identifying frailty in clinically fit patients diagnosed with hematological malignancies using a simple clinico-biological screening tool: The HEMA-4 study
27. Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR
28. Ultra-low coverage whole genome sequencing of ccfDNA in multiple myeloma: A tool for laboratory routine?
29. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network
30. Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT
31. Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma.
32. Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study
33. POSTER: MM-464 LocoMMotion: A Prospective, Observational, Multinational Study of Real-Life Current Standards of Care in Patients With Relapsed/Refractory Multiple Myeloma – Final Analysis at 2-Year Follow-Up
34. POSTER: CT-356 Idecabtagene Vicleucel (ide-cel) Versus Standard Regimens in Patients With Triple-Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa-3, a Phase III Randomized Controlled Trial (RCT)
35. POSTER: MM-508 Belantamab Mafodotin for Relapsed or Refractory Multiple Myeloma: A Real-World Observational Study Update
36. P-008 Idecabtagene vicleucel (ide-cel) vs standard regimens in triple-class–exposed (TCE) relapsed and refractory multiple myeloma (RRMM): KarMMa-3 subgroup analysis in patients receiving bridging therapy
37. P-040 Idecabtagene vicleucel (ide-cel) versus standard regimens in patients with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): a KarMMa-3 high-risk subgroup analysis
38. POSTER: MM-388 Idecabtagene Vicleucel (ide-cel) Versus Standard Regimens in Patients With Triple-Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): A KarMMa-3 Analysis in High-Risk Subgroups
39. P-325 Standard of care (SOC) outcomes in the last 3 years in patients with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM): the first pooled analysis of LocoMMotion and MoMMent trials
40. P-324 LocoMMotion: a prospective, observational, multinational study of real-life current standards of care in patients with relapsed/refractory multiple myeloma–final analysis at 2-year follow-up
41. Outcome of Second Primary Malignancies Developing in Multiple Myeloma Patients
42. MM-163 Long-Term Follow-Up From MajesTEC-1 of Teclistamab, a B-Cell Maturation Antigen (BCMA) × CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
43. MM-508 Belantamab Mafodotin for Relapsed or Refractory Multiple Myeloma: A Real-World Observational Study Update
44. P-308 Superiority of daratumumab plus lenalidomide and dexamethasone in first and second relapse in multiple myeloma patients: a real-world single centre retrospective analysis
45. CT-356 Idecabtagene Vicleucel (ide-cel) Versus Standard Regimens in Patients With Triple-Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa-3, a Phase III Randomized Controlled Trial (RCT)
46. MM-388 Idecabtagene Vicleucel (ide-cel) Versus Standard Regimens in Patients With Triple-Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): A KarMMa-3 Analysis in High-Risk Subgroups
47. P-244 Teclistamab versus Belgian real-world clinical practice in triple-class exposed relapsed and refractory multiple myeloma patients using adjusted comparison
48. P-238 A real-world observational study of belantamab mafodotin (belamaf) as a treatment for relapsed/ refractory multiple myeloma (RRMM)
49. MM-464 LocoMMotion: A Prospective, Observational, Multinational Study of Real-Life Current Standards of Care in Patients With Relapsed/Refractory Multiple Myeloma – Final Analysis at 2-Year Follow-up
50. POSTER: MM-163 Long-Term Follow-Up From MajesTEC-1 of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients With Relapsed/ Refractory Multiple Myeloma (RRMM)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.